{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:04:49Z","timestamp":1794474289950,"version":"4.9.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Therapy after failing response milestones in CML is controversial. Risks associated with comorbidities, drug toxicities or transplantation may preclude switching to another tyrosine kinase inhibitor (TKI) or other treatments. No information on long-term survival of failing patients is available. To systematically analyse survival after reaching, or not reaching, response milestones, 1342 patients from CML-study IV with newly diagnosed CML in chronic phase and regular molecular tests were studied. Landmark survival analyses were done by &lt;0.1%, 0.1\u20131%, &gt;1\u201310% and &gt;10% BCR::ABL1\n                    <jats:sup>IS<\/jats:sup>\n                    at 3, 6, 12 and 24 months up to 14 years. 10- to 12-year survival of patients who failed the failure milestones (&gt;10% BCR::ABL1\n                    <jats:sup>IS<\/jats:sup>\n                    at 6 months, &gt;1% BCR::ABL1\n                    <jats:sup>IS<\/jats:sup>\n                    at 12 months) ranged around 80%, 10% less than in responding patients. These results suggest revision of milestones. Age (more or less than 60 years) had no major impact on survival differences, but on hazard ratios and CML-specific survival. Switching to alternative therapies, which was observed in 26.9% of the patients, did not change the main results. The data show that TKI-treated patients not reaching failure milestones still may derive benefit from continuing TKI-treatment and provide a basis for individualised decisions, if failing patients are confronted with risks of alternative treatments.\n                  <\/jats:p>","DOI":"10.1038\/s41375-023-02028-2","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T13:02:21Z","timestamp":1695128541000},"page":"2231-2236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Survival with chronic myeloid leukaemia after failing milestones"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6662-7127","authenticated-orcid":false,"given":"Michael","family":"Lauseker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-0834","authenticated-orcid":false,"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-5785","authenticated-orcid":false,"given":"Susanne","family":"Sau\u00dfele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"2028_CR1","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809\u201320.","journal-title":"Blood"},{"key":"2028_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"2028_CR3","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"2028_CR4","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26:2096\u2013102.","journal-title":"Leukemia."},{"key":"2028_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30:232.","journal-title":"J Clin Oncol"},{"key":"2028_CR6","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garc\u00eda-Guti\u00e9rrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648\u201371.","journal-title":"Leukemia."},{"key":"2028_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Sau\u00dfele","year":"2015","unstructured":"Sau\u00dfele S, Krau\u00df MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015;126:42\u201349.","journal-title":"Blood."},{"key":"2028_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95:691\u2013709.","journal-title":"Am J Hematol"},{"key":"2028_CR9","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Sau\u00dfele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398\u2013406.","journal-title":"Leukemia"},{"key":"2028_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, M\u00fcller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32:415\u201323.","journal-title":"J Clin Oncol"},{"key":"2028_CR11","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L, Sau\u00dfele S, Lauseker M, M\u00fcller MC, Dietz CT, Heinrich L, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015;29:1123\u201332.","journal-title":"Leukemia."},{"key":"2028_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Sau\u00dfele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48\u201356.","journal-title":"Leukemia."},{"key":"2028_CR13","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NCP Cross","year":"2012","unstructured":"Cross NCP, White HE, M\u00fcller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26:2172\u20135.","journal-title":"Leukemia."},{"key":"2028_CR14","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1038\/s41375-021-01436-6","volume":"35","author":"EA Bruford","year":"2021","unstructured":"Bruford EA, Antonescu CR, Carroll AJ, Chinnaiyan A, Cree IA, Cross NC, et al. HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. Leukemia. 2021;35:3040\u20133.","journal-title":"Leukemia."},{"key":"2028_CR15","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00432-014-1746-8","volume":"140","author":"M Lauseker","year":"2014","unstructured":"Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, et al. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol. 2014;140:1965\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2028_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ajh.26836","volume":"98","author":"A Bidikian","year":"2023","unstructured":"Bidikian A, Jabbour E, Issa GC, Short NJ, Sasaki K, Kantarjian H. Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor. Am J Hematol. 2023;98:639\u201344.","journal-title":"Am J Hematol"},{"key":"2028_CR17","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","volume":"34","author":"R Hehlmann","year":"2020","unstructured":"Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020;34:2074\u201386.","journal-title":"Leukemia."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02028-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02028-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02028-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T04:03:20Z","timestamp":1698984200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02028-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2028"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02028-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"10 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AH: Research support from Novartis, BMS, Pfizer and Incyte. SS: Research support from Novartis, BMS, and Incyte, Honoraria from Novartis, Pfizer, Roche and Incyte.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}